Press Release
Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2016 Annual Meeting
Akebia presentation details at ASN:
|
Title: Efficacy and Dose Requirements of Vadadustat are Independent of Systemic Inflammation and Prior Erythropoiesis-Stimulating Agent (ESA) Dose in Patients With Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) |
Abstract Program #: TH-PO907 |
Session Title: CKD: Clinical Trials |
Location: Exhibit Hall |
|
Title: Vadadustat Maintains Hemoglobin (Hb) Levels in Dialysis
Dependent Chronic Kidney Disease (DD-CKD) Patients Independent of
Systemic Inflammation or |
Abstract Program #: TH-PO960 |
Session Title: Standard Hemodialysis for ESRD |
Location: Exhibit Hall |
|
Title: Pharmacokinetics (PK), Pharmacodynamics, and Safety of Single and Multiple Oral Doses of Vadadustat in Healthy Japanese and Caucasian Subjects) |
Abstract Program #: SA-PO506 |
Session Title: Pharmaco: Kinetics, Dynamics, Genomics |
Location: Exhibit Hall |
The posters will be made available at the time of the presentations by accessing Akebia's website at: http://akebia.com/media/publications/.
About Vadadustat
Vadadustat is an oral hypoxia-inducible factor (HIF) stabilizer with best-in-class potential for the treatment of anemia related to chronic kidney disease. Vadadustat, currently in development, exploits the same mechanism of action used by the body to naturally adapt to lower oxygen availability associated with a moderate increase in altitude. At higher altitudes, the body responds to lower oxygen availability with increased production of HIF, which coordinates the interdependent processes of iron mobilization and erythropoietin production to increase red blood cell production and, ultimately, improve oxygen delivery.
About Anemia Related to Chronic Kidney Disease
Approximately 30 million people in the
About
Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements include those about Akebia's strategy, future
plans and prospects, including statements regarding the potential
indications and benefits of vadadustat, and planned presentations of
data. The words "anticipate," "appear," "believe," "estimate," "expect,"
"intend," "may," "plan," "predict," "project," "target," "potential,"
"will," "would," "could," "should," "continue," and similar expressions
are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement, including the risk that existing preclinical
and clinical data may not be predictive of the results of ongoing or
later clinical trials; the ability of Akebia to successfully complete
the clinical development of vadadustat; the funding required to develop
Akebia's product candidates and operate the company, and the actual
expenses associated therewith; the cost of the Phase 3 studies of
vadadustat and the availability of financing to cover such costs; the
timing and content of decisions made by the
View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005578/en/
Akebia
AJ Gosselin, 617-844-6130
Manager, Corporate
Communications
agosselin@akebia.com
Source:
News Provided by Acquire Media
Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142
+1 617.871.2098 phone
+1 617.871.2099 fax